

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Inc.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

VOLUNTARY ANNOUNCEMENT REGARDING PROGRESS IN THE RECOVERY OF TRADE RECEIVABLE BY CHINA HEALTH GROUP INC.

The Board of Directors of the Company (the “Board”) hereby discloses the recovery progress of the Company's trade receivable (“Trade Receivable”) as of the date of this announcement and the specific measures taken, in accordance with the requirements of the inquiry letter issued by The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) on November 25, 2025 (Case No.: 20250409-F08225-0001) regarding the recovery progress of Trade Receivable as of the date of this announcement and the specific measures taken, for the reference of investors.

1. Basic Information of Trade Receivables

As disclosed in the Company's "2024 Annual Report", as at December 31, 2024, the total book value of the Company's Trade Receivables was RMB128 million, and the relevant impairment provisions have been fully provided in accordance with accounting standards. Such amounts mainly arise from the daily business operations of the Group and are common in the industry.

2. Progress of Collection Efforts

Since the disclosure of the Annual Report, the Company has continuously and actively promoted the recovery of the amounts and adopted classified measures according to the different situations of the debtors. The specific progress is as follows:

(I) Trade Receivables from Certain Related Parties

The Company has strengthened collection by establishing a special working mechanism, conducting continuous communication and sending formal letters. As at November 30, 2025, a total of RMB11,086,946 has been successfully recovered from related parties. For the remaining outstanding amounts, the Company has formally initiated arbitration proceedings which have been accepted, and is actively following up through legal channels.

(II) Trade Receivables from Non-Related Parties

For customers with good cooperative relations and positive willingness to repay: Through optimizing coordination and active negotiations, the Company has reached consensus with relevant customers and achieved continuous collection. As at the date of this announcement, the total new collection from such customers amounts to RMB4,451,430, and the subsequent repayment plans are being steadily implemented.

For customers with long-overdue Trade Receivables or operational difficulties: The Company has entrusted third-party professional institutions to conduct evaluation and disposal on a prudent basis, and has simultaneously initiated corresponding legal proceedings to safeguard its rights and interests. For amounts with high collection difficulty: The Company has adopted all legal measures in accordance with the law, including applying for including the relevant debtors in the list of persons subject to enforcement for breach of trust, and will closely monitor their asset status and take immediate action once executable clues are found.

(III) Internal Management Optimization

To fundamentally improve the quality of operating capital, the Company has established an "Trade

Receivable Management Committee" led by the finance department and collaborated with multiple departments, specifically responsible for collection work; and has strengthened the full-process internal control from customer credit evaluation to account period management to prevent new risks.

3. Subsequent Plans

The Company will continue to take all necessary measures in accordance with laws and regulations, including but not limited to continuous negotiations, promoting the execution of arbitration awards, and preparing civil lawsuits, to maximize the recovery of the amounts. The Company will regularly report the progress to the Board and promptly fulfill its information disclosure obligations in accordance with the Stock Exchange Rules.

4. Risk Warning

The final recovery result of the Trade receivables may be affected by various factors and is subject to uncertainty. Investors are advised to pay attention to investment risks.

By Order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 1 December 2025

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Mr. Raymond Guo; one non-executive Director, being Dr. ZHANG Li; and four independent non-executive Directors, being Dr. NI Binhui, Mr. WU Shuangsi, Dr. GUO Tong and Ms. LIU Na.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for 7 days from the date of its posting. This announcement will also be posted on the Company's website at <http://www.chgi.net>.